207 results on '"Singal, Amit G."'
Search Results
2. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
3. Effect of Hospital Cancer Designation on use of Multimodal Therapy and Survival of Metastatic Colorectal Cancer: A State-Wide Analysis
4. ASO Visual Abstract: Effect of Hospital Cancer Designation on Use of Multimodal Therapy and Survival of Patients with Metastatic Colorectal Cancer: A State-Wide Analysis
5. Impact of the Early COVID-19 Pandemic on Incidence and Outcomes of Hepatocellular Carcinoma in the United States
6. Evolving trends in CT colonography: A 10-year analysis of use and associated factors
7. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk
8. PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer
9. Financial Burden of Hepatocellular Carcinoma Screening in Patients With Cirrhosis
10. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
11. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
12. Hepatocellular Carcinoma Surveillance Patterns and Outcomes in Patients With Cirrhosis
13. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis
14. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC
15. Performance of a Multi-cancer Early Detection Test for Detection of Hepatocellular Carcinoma in Patients With Cirrhosis
16. COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States
17. Hepatocellular Carcinoma Surveillance: Evidence-Based Tailored Approach
18. Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma
19. The Authors’ Reply
20. Racial and Ethnic Disparities in Liver Transplantation for Alcohol-associated Liver Diseases in the United States
21. Psychiatric disorders in patients with hepatocellular carcinoma: A large US cohort of commercially insured individuals
22. Prognostic Value of Liver Biomarkers in Hepatocellular Carcinoma Patients Undergoing Yttrium 90 Transarterial Radioembolization (TARE): A Retrospective Pilot Study
23. Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial
24. Downstaging with Atezolizumab-Bevacizumab: A Case Series
25. Clinician-Level Knowledge and Barriers to Hepatocellular Carcinoma Surveillance
26. Role of biomarkers in the diagnosis and management of HCC
27. Evidence and Choice: The BCLC Vision for Tailoring Clinical Decision-Making
28. The Future Role of Abdominal US in Hepatocellular Carcinoma Surveillance
29. Systemic Therapies for Hepatocellular Carcinoma in India
30. Supplementary Figure 3 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
31. Supplementary Table 1 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
32. Supplementary Figure 5 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
33. Data from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
34. Supplementary Figure 2 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
35. Supplementary Table 2 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
36. Supplementary Figure 1 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
37. Supplementary Figure 4 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
38. Brief alcohol interventions are underutilized in persons with nonalcohol-associated chronic liver diseases
39. Implementation of a Hepatocellular Carcinoma Surveillance Program in a Community-Based Integrated Health System in Patients With Hepatitis C Cirrhosis.
40. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.
41. Defining the Role of Social Vulnerability in Treatment and Survival in Localized Colon Cancer
42. Implementation of a Hepatocellular Carcinoma Surveillance Program in a Community-Based Integrated Health System in Patients With Hepatitis C Cirrhosis
43. Racial and ethnic disparities in alcohol-associated liver disease in the United States: A systematic review and meta-analysis
44. Pan-cancer molecular signatures connecting aspartate transaminase (AST) to cancer prognosis, metabolic and immune signatures
45. Artificial intelligence in liver cancer research: a scientometrics analysis of trends and topics
46. Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis
47. Comparing first-line (1L) atezolizumab plus bevacizumab (A+B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database.
48. Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study.
49. Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network.
50. Racial/ethnic disparities in the effectiveness of atezolizumab plus bevacizumab (A+B) vs. tyrosine kinase inhibitors (TKIs) among veterans with unresectable hepatocellular carcinoma (uHCC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.